• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

U.S. Funds 10 Million USD to Increase Vaccine Manufacturing Capacity

sharon sanders

Editor-in-Chief & President
Date: April 24, 2007
For Release: Immediately
Contact: HHS Press Office


STATEMENT BY MIKE LEAVITT
Secretary of Health and Human Services
On the Grants Awarded by the World Health Organization to
Increase Global Manufacturing Capacity to Produce Influenza Vaccines


The World Health Organization (WHO) has taken an important step forward
in the global effort to prepare for an influenza pandemic by awarding up
to $15 million in grants to six nations to support the establishment or
expansion of domestic manufacturing capacity for influenza vaccine.
Once this production capacity is in place, these countries will be able
to make seasonal influenza vaccine domestically under the standards of
good manufacturing practices, to protect their populations. Some could
be in a position also to export vaccine to their neighbors. Most
importantly, should an influenza pandemic emerge, they will have the
infrastructure in place to convert their production lines to
manufacturing pandemic vaccine.

I am proud the United States, through my Department, was able to
contribute $10 million to support this funding.

The current global manufacturing capacity for influenza vaccine is far
short of the capacity needed to protect the world's six billion people
in the event of an influenza pandemic. In the United States, we have
been making significant investments in vaccine research and development
and in expanding influenza vaccine production surge capacity, including
$1.3 billion in cell-based vaccine and antigen-sparing influenza
advanced development efforts. These investments will likely benefit not
only citizens of the United States, but also citizens of the world.

But responding to a pandemic will demand the cooperation of the world
community. No nation can go it alone. I commend WHO Director-General
Dr. Margaret Chan for her continued leadership in guiding these efforts,
but all of us need to do much more as global partners to ensure we are
better prepared tomorrow than we are today.
 
Back
Top